Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin- cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results

Journal of the National Cancer Institute

Volumn 92, Issue 9, 2000, Pages 699-708

  Piccart, Martine J ^a,d   Bertelsen, Kamma ^e   James, Keith ^b   Cassidy, Jim ^c   Mangioni, Constantino ^a   Simonsen, Ernst ^e   Stuart, Gavin ^b   Kaye, Stan ^c   Vergote, Ignace ^a   Blom, René ^e   Grimshaw, Robert ^b   Atkinson, Ronald J ^c   Swenerton, Ken D ^b   Trope, Claes ^e   Nardi, Mario ^a   Kaern, Janne ^e   Tumolo, Salvatore ^a   Timmers, Petra ^a   Roy, Josée Anne ^a   Lhoas, François ^a   Lindvall, Berit ^e   Bacon, Monica ^b   Birt, Angelo ^c   Andersen, Joern Erik ^e   Zee, Benny ^b   Paul, James ^c   Baron, Benoît ^a   Pecorelli, Sergio ^a   more..

^a EORTC DATA CENTER   (Belgium)

^b QUEEN S UNIVERSITY   (Canada)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^d JULES BORDET INSTITUTE   (Belgium)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; MULTICENTER STUDY; OVARY CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0034600305     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.9.699     Document Type: Article

References (19)

1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Look KY, Partridge EE, et al. A phase III trial comparing cisplatin/cytoxan (PC) and cisplatin/taxol (PT) in advanced ovarian cancer (AOC) [abstract]. Proc ASCO 1993;12: abstract 808.
2. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, ct al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
3. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
4. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
5. Cox DR. Regression models and life-tables. J R Stat Soc 1972;B34: 187-202.
6. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med 1995;14:1707-23.
7. Bartolucci A. Estimation and comparison of proportions. In: Buyse M, Staquet M. Sylvester R, editors. Cancer clinical trials, methods and practice. Oxford (U.K.): Oxford University Press: 1984. p. 337-60.
8. Kruskal WH, Wallis WA. Use of ranks in one criterion variance analysis. J Am Stat Assoc 1952;47:583-92.
9. van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629-34.
10. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-66.
11. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000;18:106-15.
12. ICON collaborators. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. International Collaborative Ovarian Neoplasm Study. Lancet 1998;352:1571-6.
13. Sandercock J, Parmer MK, Torri V. First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. Br J Cancer 1998; 78:1471-8.
14. Piccart MJ, McGuire WP. ICON trial. EORTC-GCCG. NOCOVA, NCI-C, Scottish groups, and GOG. Gynaecologic Oncology Group. Lancet 1999; 353:587; discussion 588.
15. rd International Collaborative Ovarian Neoplasm Study (ICON3) [abstract]. Proc ASCO 1999;18:abstract 1375.
16. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, et al. Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999;10 Suppl 1:87-92.
17. du Bois A, Neijt JP, Thigpen JT First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - a new standard of care? Ann Oncol 1999;10 Suppl 1:35-41.
18. Ozols RF, Bundy BN, Fowler J, Clarke-Pearson D, Mannel R. Hartenbach EM, et al. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group Trial (GOG 158) [abstract]. Proc ASCO 1999;18:abstract 1373.
19. Piccart MJ, Stuart GC, Cassidy J, Bertelsen K, Parmar MK, Eisenhauer EA, et al. Intergroup collaboration in ovarian cancer: a giant step forward. Ann Oncol 1999;10 Suppl 1:83-6.